Research programme: hepatitis C translation inhibitors - PTC Therapeutics
Alternative Names: Hepatitis C mRNA antagonists - PTC Therapeutics; PTC 725Latest Information Update: 22 Jan 2015
At a glance
- Originator PTC Therapeutics
- Class Small molecules
- Mechanism of Action Protein synthesis inhibitors; Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 15 Jul 2014 Discontinued - Preclinical for Hepatitis C in USA (PO)
- 10 Aug 2009 Development candidate designated from research collaboration between PTC Therapeutics and Schering-Plough for the treatment of Hepatitis C
- 28 Aug 2007 This programme is still in active development